PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43

Human Molecular Genetics

Volumn 24, Issue 6, 2015, Pages 1741-1754

  Joardar, Archi ^a   Menzl, Judith ^a   Podolsky, Taylor C ^a   Manzo, Ernesto ^a   Estes, Patricia S ^a   Ashford, Sarah ^a   Zarnescu, Daniela C ^a,b,c  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; FUSED IN SARCOMA PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA E75; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA E78; PIOGLITAZONE; TAR DNA BINDING PROTEIN; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; DNA BINDING PROTEIN; DROSOPHILA PROTEIN; E78 PROTEIN, DROSOPHILA; EIP75B PROTEIN, DROSOPHILA; FUS PROTEIN, HUMAN; NEUROPROTECTIVE AGENT; RNA BINDING PROTEIN FUS; TBPH PROTEIN, DROSOPHILA; TRANSCRIPTION FACTOR;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; EVIDENCE BASED PRACTICE; FEMALE; FRUIT FLY MODEL; GENE EXPRESSION; GLIA CELL; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; LETHALITY; LIFESPAN; LOCOMOTION; MALE; METABOLITE; METABOLOMICS; MOLECULARLY TARGETED THERAPY; MOTONEURON; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SURVIVAL; TDP 43 PROTEINOPATHY; AGONISTS; ANIMAL; DISEASE MODEL; DROSOPHILA; DRUG EFFECTS; GENETICS; GLIA; HUMAN; METABOLISM;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DROSOPHILA; DROSOPHILA PROTEINS; HUMANS; MOTOR NEURONS; NEUROGLIA; NEUROPROTECTIVE AGENTS; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA-BINDING PROTEIN FUS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 84936076189     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu587     Document Type: Article

References (72)

1. Sreedharan, J. and Brown, R.H. Jr. (2013) Amyotrophic lateral sclerosis: problems and prospects. Ann. Neurol., 74, 309-316.
2. Alexander, M.D., Traynor, B.J., Miller, N., Corr, B., Frost, E., McQuaid, S., Brett, F.M., Green, A. and Hardiman, O. (2002) "True" sporadic ALS associated with a novel SOD-1 mutation. Ann. Neurol., 52, 680-683.
3. Lagier-Tourenne, C. and Cleveland, D.W. (2009) Rethinking ALS: the FUS about TDP-43. Cell, 136, 1001-1004.
4. Renton, A.E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L. et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron, 72, 257-268.
5. Wu, C.H., Fallini, C., Ticozzi, N., Keagle, P.J., Sapp, P.C., Piotrowska, K., Lowe, P., Koppers, M., McKenna-Yasek, D., Baron, D.M. et al. (2012) Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature, 488, 499-503.
6. Kwiatkowski, T.J. Jr., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E. J., Munsat, T. et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science, 323, 1205-1208.
7. Janssens, J. and Van Broeckhoven, C. (2013) Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum. Mol. Genet., 22, R77-R87.
8. Kabashi, E., Valdmanis, P.N., Dion, P., Spiegelman, D., McConkey, B.J., Vande Velde, C., Bouchard, J.P., Lacomblez, L., Pochigaeva, K., Salachas, F. et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet., 40, 572-574.
9. Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314, 130-133.
10. Sreedharan, J., Blair, I.P., Tripathi, V.B., Hu, X., Vance, C., Rogelj, B., Ackerley, S., Durnall, J.C., Williams, K.L., Buratti, E. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 319, 1668-1672.
11. Van Deerlin, V.M., Leverenz, J.B., Bekris, L.M., Bird, T.D., Yuan, W., Elman, L.B., Clay, D., Wood, E.M., Chen-Plotkin, A.S., Martinez-Lage, M. et al. (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol., 7, 409-416.
12. King, O.D., Gitler, A.D. and Shorter, J. (2012) The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res., 1462, 61-80.
13. Ou, S.H., Wu, F., Harrich, D., Garcia-Martinez, L.F. and Gaynor, R.B. (1995) Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol., 69, 3584-3596.
14. Buratti, E. and Baralle, F.E. (2001) Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J. Biol. Chem., 276, 36337-36343.
15. Lee, E.B., Lee, V.M. and Trojanowski, J.Q. (2012) Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci., 13, 38-50.
16. Polymenidou, M., Lagier-Tourenne, C., Hutt, K.R., Huelga, S.C., Moran, J., Liang, T.Y., Ling, S.C., Sun, E., Wancewicz, E., Mazur, C. et al. (2011) Long pre-mRNA depletion and RNAmissplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci., 14, 459-468.
17. Tollervey, J.R., Curk, T., Rogelj, B., Briese, M., Cereda, M., Kayikci, M., Konig, J., Hortobagyi, T., Nishimura, A.L., Zupunski, V. et al. (2011) Characterizing the RNA targets and positiondependent splicing regulation by TDP-43. Nat. Neurosci., 14, 452-458.
18. Colombrita, C., Onesto, E., Tiloca, C., Ticozzi, N., Silani, V. and Ratti, A. (2011) RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis. Arch. Ital. Biol., 149, 83-99.
19. Voigt, A., Herholz, D., Fiesel, F.C., Kaur, K., Muller, D., Karsten, P., Weber, S.S., Kahle, P.J., Marquardt, T. and Schulz, J.B. (2010) TDP-43-mediated neuron loss in vivo requires RNA-binding activity. PLoS One, 5, e12247.
20. Ling, S.C., Polymenidou, M. and Cleveland, D.W. (2013) Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron, 79, 416-438.
21. Pollari, E., Goldsteins, G., Bart, G., Koistinaho, J. and Giniatullin, R. (2014) The role of oxidative stress in degeneration of the neuromuscular junction in amyotrophic lateral sclerosis. Front. Cell. Neurosci., 8, 131.
22. Stoica, R., De Vos, K.J., Paillusson, S., Mueller, S., Sancho, R.M., Lau, K.F., Vizcay-Barrena, G., Lin, W.L., Xu, Y.F., Lewis, J. et al. (2014) ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTDassociated TDP-43. Nat. Commun., 5, 3996.
23. Tadic, V., Prell, T., Lautenschlaeger, J. and Grosskreutz, J. (2014) The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Front. Cell. Neurosci., 8, 147.
24. Prell, T., Lautenschlager, J., Weidemann, L., Ruhmer, J., Witte, O.W. and Grosskreutz, J. (2014) Endoplasmic reticulum stress is accompanied by activation of NF-kappaB in amyotrophic lateral sclerosis. J. Neuroimmunol., 270, 29-36.
25. Ari, C., Poff, A.M., Held, H.E., Landon, C.S., Goldhagen, C.R., Mavromates, N. andD'Agostino, D.P. (2014) Metabolic therapy with Deanna protocol supplementation delays disease progression and extends survival in Amyotrophic Lateral Sclerosis (ALS) mouse model. PLoS One, 9, e103526.
26. Lekoubou, A., Matsha, T.E., Sobngwi, E. and Kengne, A.P. (2014) Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review. BMC Res. Notes, 7, 171.
27. Lim, M.A., Bence, K.K., Sandesara, I., Andreux, P., Auwerx, J., Ishibashi, J., Seale, P. and Kalb, R.G. (2014) Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of Amyotrophic Lateral Sclerosis. Hum. Mol. Genet., 23, 4995-5008.
28. Wills, A.M., Hubbard, J., Macklin, E.A., Glass, J., Tandan, R., Simpson, E.P., Brooks, B., Gelinas, D., Mitsumoto, H., Mozaffar, T. et al. (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet, 383, 2065-2072.
29. Lawton, K.A., Cudkowicz, M.E., Brown, M.V., Alexander, D., Caffrey, R., Wulff, J.E., Bowser, R., Lawson, R., Jaffa, M., Milburn, M.V. et al. (2012) Biochemical alterations associated with ALS. ALS, 13, 110-118.
30. Bouteloup, C., Desport, J.C., Clavelou, P., Guy, N., Derumeaux-Burel, H., Ferrier, A. and Couratier, P. (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J. Neurol., 256, 1236-1242.
31. Dupuis, L., Oudart, H., Rene, F., Gonzalez de Aguilar, J.L. and Loeffler, J.P. (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl Acad. Sci. USA, 101, 11159-11164.
32. Jawaid, A., Salamone, A.R., Strutt, A.M., Murthy, S.B., Wheaton, M., McDowell, E.J., Simpson, E., Appel, S.H., York, M.K. and Schulz, P.E. (2010) ALS disease onset may occur later in patients with pre-morbid diabetes mellitus. Eur. J. Neurol, 17, 733-739.
33. Estes, P.S., Boehringer, A., Zwick, R., Tang, J.E., Grigsby, B. and Zarnescu, D.C. (2011) Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum. Mol. Gen., 20, 2308-2321.
34. Li, Y., Ray, P., Rao, E.J., Shi, C., Guo, W., Chen, X., Woodruff, E. A. 3rd, Fushimi, K. and Wu, J.Y. (2010) A Drosophila model for TDP-43 proteinopathy. Proc. Natl Acad. Sci. USA, 107, 3169-3174.
35. Estes, P.S., Daniel, S.G., McCallum, A.P., Boehringer, A.V., Sukhina, A.S., Zwick, R.A. and Zarnescu, D.C. (2013) Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a Drosophila model of amyotrophic lateral sclerosis. Dis. Model. Mech., 6, 721-733.
36. Jia, Z., Sun, Y., Yang, G., Zhang, A., Huang, S., Heiney, K.M. and Zhang, Y. (2014) New insights into the PPAR gamma agonists for the treatment of diabetic nephropathy. PPAR Res., 2014, 818530.
37. Staels, B. and Fruchart, J.C. (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 54, 2460-2470.
38. Forman, B.M., Chen, J. and Evans, R.M. (1996) The peroxisome proliferator-activated receptors: ligands and activators. Ann. N. Y. Acad. Sci., 804, 266-275.
39. Kapadia, R., Yi, J.H. and Vemuganti, R. (2008) Mechanisms of anti-inflammatory and neuroprotective actions of PPARgamma agonists. Front. Biosci., 13, 1813-1826.
40. Rutherford, N.J., Zhang, Y.J., Baker, M., Gass, J.M., Finch, N.A., Xu, Y.F., Stewart, H., Kelley, B.J., Kuntz, K., Crook, R.J. et al. (2008) Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet., 4, e1000193.
41. Gustafson, K. and Boulianne, G.L. (1996) Distinct expression patterns detected within individual tissues by the GAL4 enhancer trap technique. Genome, 39, 174-182.
42. Dupuis, L., Dengler, R., Heneka, M.T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M. et al. (2012) A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One, 7, e37885.
43. Boyer, J.G., Ferrier, A. and Kothary, R. (2013) More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases. Front. Physiol., 4, 356.
44. Philips, T. and Rothstein, J.D. (2014) Glial cells in amyotrophic lateral sclerosis. Exp Neurol, 262, 111-120.
45. Budnik, V., Koh, Y.H., Guan, B., Hartmann, B., Hough, C., Woods, D. and Gorczyca, M. (1996) Regulation of synapse structure and function by the Drosophila tumor suppressor gene dlg. Neuron, 17, 627-640.
46. Lanson, N.A. Jr., Maltare, A., King, H., Smith, R., Kim, J.H., Taylor, J.P., Lloyd, T.E. and Pandey, U.B. (2011) ADrosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43. Hum. Mol. Genet., 20, 2510-2523.
47. Wang, J.W., Brent, J.R., Tomlinson, A., Shneider, N.A. and McCabe, B.D. (2011) The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span. J. Clin. Invest., 121, 4118-4126.
48. Kiaei, M., Kipiani, K., Chen, J., Calingasan, N.Y. and Beal, M.F. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 191, 331-336.
49. Schutz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G.E., Schurmann, B., Zimmer, A. and Heneka, M.T. (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci., 25, 7805-7812.
50. Watson, M.R., Lagow, R.D., Xu, K., Zhang, B. and Bonini, N.M. (2008) A drosophila model for amyotrophic lateral sclerosis reveals motor neuron damage by human SOD1. J. Biol. Chem., 283, 24972-24981.
51. Bruijn, L.I., Becher, M.W., Lee, M.K., Anderson, K.L., Jenkins, N. A., Copeland, N.G., Sisodia, S.S., Rothstein, J.D., Borchelt, D.R., Price, D.L. et al. (1997) ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron, 18, 327-338.
52. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X. et al. (1994) Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science, 264, 1772-1775.
53. Gillies, P.S. and Dunn, C.J. (2000) Pioglitazone. Drugs, 60, 333-343. discussion 344-335.
54. Gray, E., Ginty, M., Kemp, K., Scolding, N. and Wilkins, A. (2012) The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function. J. Neuroinflammation, 9, 63.
55. Colca, J.R., McDonald, W.G., Waldon, D.J., Leone, J.W., Lull, J.M., Bannow, C.A., Lund, E.T. and Mathews, W.R. (2004) Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab., 286, E252-E260.
56. Garcia-Ruiz, I., Solis-Munoz, P., Fernandez-Moreira, D., Munoz-Yague, T. and Solis-Herruzo, J.A. (2013) Pioglitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain. BMC Biol., 11, 88.
57. King-Jones, K. and Thummel, C.S. (2005) Nuclear receptors-a perspective from Drosophila. Nat. Rev. Genet., 6, 311-323.
58. Rothstein, J.D. (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 65 (Suppl 1), S3-S9.
59. Blokhuis, A.M., Groen, E.J., Koppers, M., van den Berg, L.H. and Pasterkamp, R.J. (2013) Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol., 125, 777-794.
60. Zhao, Z., Lange, D.J., Voustianiouk, A., MacGrogan, D., Ho, L., Suh, J., Humala, N., Thiyagarajan, M., Wang, J. and Pasinetti, G.M. (2006) A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci., 7, 29.
61. Renton, A.E., Chio, A. and Traynor, B.J. (2014) State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci., 17, 17-23.
62. Benatar, M. (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis., 26, 1-13.
63. Scott, S., Kranz, J.E., Cole, J., Lincecum, J.M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al-Nakhala, B.M., Vieira, F.G. et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler., 9, 4-15.
64. Kabashi, E., Bercier, V., Lissouba, A., Liao, M., Brustein, E., Rouleau, G.A. and Drapeau, P. (2011) FUS and TARDBP but not SOD1 interact in genetic models of amyotrophic lateral sclerosis. PLoS Genet., 7, e1002214.
65. Levine, T.D., Bowser, R., Hank, N.C., Gately, S., Stephan, D., Saperstein, D.S. and Van Keuren-Jensen, K. (2012) A pilot trial of pioglitazone HCl and tretinoin in ALS: cerebrospinal fluid biomarkers to monitor drug efficacy and predict rate of disease progression. Neurol. Res. Int, 2012, 582075.
66. Karak, M., Bal, N.C., Bal, C. and Sharon, A. (2013) Targeting peroxisome proliferator-activated receptor gammafor generation of antidiabetic drug. Curr. Diabetes Rev., 9, 275-285.
67. Romera, C., Hurtado, O., Mallolas, J., Pereira, M.P., Morales, J.R., Romera, A., Serena, J., Vivancos, J., Nombela, F., Lorenzo, P. et al. (2007) Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J. Cereb. Blood Flow Metab., 27, 1327-1338.
68. Jitrapakdee, S., Slawik, M., Medina-Gomez, G., Campbell, M., Wallace, J.C., Sethi, J.K., O'Rahilly, S. and Vidal-Puig, A.J. (2005) The peroxisome proliferator-activated receptorgamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro. J. Biol. Chem., 280, 27466-27476.
69. Jawaid, A., Murthy, S.B., Wilson, A.M., Qureshi, S.U., Amro, M.J., Wheaton, M., Simpson, E., Harati, Y., Strutt, A.M., York, M.K. et al. (2010) A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. Amyotroph. Lateral Scler., 11, 542-548.
70. Brand, A.H. and Perrimon, N. (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development, 118, 401-415.
71. Shin, S.Y., Fauman, E.B., Petersen, A.K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I., Forgetta, V., Yang, T.P. et al. (2014) An atlas of genetic influences on human blood metabolites. Nat. Genet., 46, 543-550.
72. Storey, J.D. and Tibshirani, R. (2003) Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA, 100, 9440-9445.